title: Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.
abstract: BACKGROUND
  Hyperglycemia and new-onset diabetes mellitus have been reported to occur in HIV-infected patients treated with protease inhibitors.
  
  
  OBJECTIVE
  To determine the effect of protease inhibitor therapy on serum glucose in a predominantly minority patient population.
  
  
  METHODS
  Retrospective record review.
  
  
  METHODS
  Clinical HIV program of an urban Veterans Affairs medical center.
  
  
  METHODS
  All HIV-infected patients receiving a protease inhibitor over a one-year period from September 1996 through August 1997.
  
  
  RESULTS
  One hundred seventeen patients not previously known to be diabetic received protease inhibitors; seven (6%) developed symptomatic diabetes mellitus. Eight other patients had one or more serum glucose values >150 mg/dL. Mean random glucose values for patients who did not develop diabetes were higher during therapy than prior to initiation of protease inhibitors.
  
  
  CONCLUSIONS
  Urban minority HIV-infected patients receiving combination antiretroviral therapy including a protease inhibitor may be at increased risk for the development of hyperglycemia and diabetes mellitus. Risk factors for diabetes mellitus should be identified and blood glucose monitored in all patients receiving protease inhibitors.
authors.affiliation: Infectious Diseases Clinic, Veterans Affairs New Jersey Health Care System, East Orange 07018, USA. dever.lisa@east-orange.va.gov
authors.forename: L L
authors.initials: LL
authors.lastname: Dever
authors.forename: P A
authors.initials: PA
authors.lastname: Oruwari
authors.forename: W E
authors.initials: WE
authors.lastname: Figueroa
authors.forename: C A
authors.initials: CA
authors.lastname: O'Donovan
authors.forename: R H
authors.initials: RH
authors.lastname: Eng
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced*; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008913:Minority Groups / Q000706:statistics & numerical data; D012189:Retrospective Studies; D012307:Risk Factors; D019438:Ritonavir / Q000009:adverse effects / Q000627:therapeutic use; D019258:Saquinavir / Q000009:adverse effects / Q000627:therapeutic use; D014505:Urban Population / Q000706:statistics & numerical data
chemical_list: D001786:Blood Glucose; D017320:HIV Protease Inhibitors; D019469:Indinavir; D019258:Saquinavir; D019438:Ritonavir